Literature DB >> 28422300

Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study.

Cosmo Godino1, Anna Giulia Pavon1, Antonio Mangieri1, Anna Salerno1, Michela Cera1, Alberto Monello1, Alaide Chieffo1, Valeria Magni1, Alberto Cappelletti1, Alberto Margonato1, Antonio Colombo1,2.   

Abstract

BACKGROUND: The acute effects of statin loading dose (LD) on platelet reactivity in patients with chronic stable angina (CSA) are not completely clear. HYPOTHESIS: We hypothesized that LDs of atorvastatin and rosuvastatin have different pharmacodynamic acute effects on platelet aggregability in CSA patients with baseline normal platelet reactivity while on dual antiplatelet therapy (DAPT).
METHODS: From September 2011 to February 2014, all consecutive CSA patients on chronic DAPT (aspirin and clopidogrel) were evaluated before elective percutaneous coronary intervention (PCI). An initial assessment of platelet reactivity in response to thrombin receptor agonist, ADP, and ASP (respectively, indicative of the response to clopidogrel and aspirin) was performed with impedance aggregometry. Patients with high platelet reactivity to ADP test (area under the curve >47) were excluded. The remaining patients were randomized into 3 treatment groups: Group A, atorvastatin LD 80 mg; Group B, rosuvastatin LD 40 mg; and Group C, no statin LD (control group). A second assessment of platelet reactivity was performed ≥12 hours after statin LD.
RESULTS: 682 patients were screened and 145 were randomized into the 3 groups. At baseline and after statin LD, no significant difference was found in platelet reactivity in response to 3 different agonists between the 3 groups. Subgroup analysis showed that platelet reactivity to ADP test was significantly lower in patients chronically treated with low-dose statins (n = 94) compared with statin-naïve patients (n = 51; 15.32 ± 1.50 vs 18.59 ± 1.30; P = 0.007).
CONCLUSIONS: Loading dose of atorvastatin (80 mg) or rosuvastatin (40 mg) did not induce significant variation in platelet reactivity in CSA patients with baseline reduced platelet reactivity as in chronic DAPT. Our data confirm that chronic concomitant treatment with low-dose statins and clopidogrel resulted in significantly lower platelet reactivity compared with clopidogrel alone.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Atorvastatin; Clopidogrel; Platelet Reactivity; Rosuvastatin

Mesh:

Substances:

Year:  2017        PMID: 28422300      PMCID: PMC6490637          DOI: 10.1002/clc.22709

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  22 in total

1.  Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?

Authors:  Michael Piorkowski; Sabine Fischer; Caroline Stellbaum; Markus Jaster; Peter Martus; Andreas J Morguet; Heinz-Peter Schultheiss; Ursula Rauch
Journal:  J Am Coll Cardiol       Date:  2007-02-23       Impact factor: 24.094

2.  Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.

Authors:  Francesco Pelliccia; Giuseppe Rosano; Giuseppe Marazzi; Cristiana Vitale; Ilaria Spoletini; Ferdinando Franzoni; Giuseppe Speziale; Marina Polacco; Cesare Greco; Carlo Gaudio
Journal:  Eur J Pharmacol       Date:  2014-01-17       Impact factor: 4.432

3.  Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.

Authors:  Yongwhi Park; Young-Hoon Jeong; Udaya S Tantry; Jong Hwa Ahn; Tae Jung Kwon; Jeong Rang Park; Seok-Jae Hwang; Eun-Ha Gho; Kevin P Bliden; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim; Paul A Gurbel
Journal:  Eur Heart J       Date:  2012-04-16       Impact factor: 29.983

Review 4.  Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.

Authors:  Benjamin Sadowitz; Kristopher G Maier; Vivian Gahtan
Journal:  Vasc Endovascular Surg       Date:  2010-05       Impact factor: 1.089

5.  Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood.

Authors:  Orsolya Tóth; Andreas Calatzis; Sandra Penz; Hajna Losonczy; Wolfgang Siess
Journal:  Thromb Haemost       Date:  2006-12       Impact factor: 5.249

6.  ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin.

Authors:  Michael Piorkowski; Ulf Weikert; Peter-Lothar Schwimmbeck; Peter Martus; Heinz-Peter Schultheiss; Ursula Rauch
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

7.  Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.

Authors:  Vincenzo Pasceri; Giuseppe Patti; Annunziata Nusca; Christian Pristipino; Giuseppe Richichi; Germano Di Sciascio
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

8.  Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.

Authors:  Giuseppe Patti; Vincenzo Pasceri; Giuseppe Colonna; Marco Miglionico; Dionigi Fischetti; Gennaro Sardella; Antonio Montinaro; Germano Di Sciascio
Journal:  J Am Coll Cardiol       Date:  2007-03-27       Impact factor: 24.094

9.  Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.

Authors:  Rickard E Malmström; J Ostergren; L Jørgensen; P Hjemdahl
Journal:  J Intern Med       Date:  2009-06-22       Impact factor: 8.989

10.  Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention.

Authors:  Rolf P Kreutz; Jeffrey A Breall; Anjan Sinha; Elisabeth von der Lohe; Richard J Kovacs; David A Flockhart
Journal:  Clin Pharmacol       Date:  2016-06-03
View more
  4 in total

1.  Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study.

Authors:  Cosmo Godino; Anna Giulia Pavon; Antonio Mangieri; Anna Salerno; Michela Cera; Alberto Monello; Alaide Chieffo; Valeria Magni; Alberto Cappelletti; Alberto Margonato; Antonio Colombo
Journal:  Clin Cardiol       Date:  2017-04-19       Impact factor: 2.882

2.  TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study.

Authors:  Naveen Seecheran; Victoria Seebalack; Rajeev Seecheran; Aarti Maharaj; Brent Boodhai; Valmiki Seecheran; Sangeeta Persad; Shastri Motilal; Antonio Tello-Montoliu; David Schneider
Journal:  Cardiol Ther       Date:  2019-07-10

3.  Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke.

Authors:  Lanying He; Ronghua Xu; Jian Wang; Lili Zhang; Lijuan Zhang; Wang Zhao; Weiwei Dong
Journal:  BMC Neurol       Date:  2019-10-18       Impact factor: 2.474

4.  Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

Authors:  Georg Gelbenegger; Marek Postula; Ladislav Pecen; Sigrun Halvorsen; Maciej Lesiak; Christian Schoergenhofer; Bernd Jilma; Christian Hengstenberg; Jolanta M Siller-Matula
Journal:  BMC Med       Date:  2019-11-04       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.